A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy

Hézode et al. recently reported the frequent occurrence of anemia and thrombocytopenia in the ANRS-CO20-CUPIC cohort of hepatitis C virus (HCV) cirrhotic experienced patients treated with pegylated-interferon (Peg-IFN), ribavirin (RBV), and telaprevir or boceprevir.1,2 Using frequent measurements of...

Descripción completa

Detalles Bibliográficos
Autores principales: Laouénan, C, Guedj, J, Peytavin, G, Nguyen, TH Tram, Lapalus, M, Khelifa-Mouri, F, Boyer, N, Zoulim, F, Serfaty, L, Bronowicki, J-P, Martinot-Peignoux, M, Lada, O, Asselah, T, Dorival, C, Hézode, C, Carrat, F, Nicot, F, Marcellin, P, Mentré, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369757/
https://www.ncbi.nlm.nih.gov/pubmed/26225222
http://dx.doi.org/10.1002/psp4.8
Descripción
Sumario:Hézode et al. recently reported the frequent occurrence of anemia and thrombocytopenia in the ANRS-CO20-CUPIC cohort of hepatitis C virus (HCV) cirrhotic experienced patients treated with pegylated-interferon (Peg-IFN), ribavirin (RBV), and telaprevir or boceprevir.1,2 Using frequent measurements of serum drug concentrations, hemoglobin, and platelet concentrations obtained in 15 patients of this cohort, we show how an on-treatment model-based approach could be used to individualize dose regimen and avoid the occurrence of RBV-induced anemia and Peg-IFN-induced thrombocytopenia.

Ejemplares similares